Understanding kidney disease linked to COVID-19 in certain populations
Official title: Identification of Host-Specific Determinants of APOL1-associated COVAN
Funded at Duke University · NIH-11061335 · Data updated 2026-11-12
This study is looking at how certain genes, especially the APOL1 gene, might affect kidney health after COVID-19, particularly in African American and Hispanic people, to help find better ways to treat and prevent kidney problems.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | April 1, 2024 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $153,306 |
| NIH project number | 5K08DK136924-02 |
| Project ID | NIH-11061335 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of African American or Hispanic ancestry who have experienced kidney issues following COVID-19 infection.
✕Less likely to help
Patients who do not have a history of COVID-19 or those without the specific genetic variants associated with APOL1 may not benefit from this research.
What this research studies
This research investigates how specific genetic factors, particularly variations in the APOL1 gene, contribute to kidney disease following COVID-19 infection, especially in individuals of African American and Hispanic descent. The study aims to identify the mechanisms by which these genetic variants lead to kidney damage and failure, focusing on the role of immune responses and inflammatory cytokines. By analyzing patient samples and using advanced laboratory techniques, the researchers hope to uncover critical insights that could inform future treatments and preventive strategies for affected individuals.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and treatment options for kidney disease related to COVID-19, particularly for at-risk populations.
How similar studies have gone: Previous research has shown that genetic factors like APOL1 variants significantly impact kidney disease outcomes, suggesting that this study builds on established findings in the field.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Nystrom, Sarah — Duke University
- Study coordinator: Nystrom, Sarah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.